Effect of daily azithromycin therapy and adherence on readmission risk in COPD

TY - JOUR

T1 - Effect of daily azithromycin therapy and adherence on readmission risk in COPD

AU - the COPD Clinical Research Network Investigators

AU - Krishnan, Jamuna K.

AU - Voelker, Helen

AU - Connett, John E.

AU - Niewoehner, Dennis E.

AU - Albert, Richard K.

AU - Scanlon, Paul D.

AU - Criner, Gerard J.

AU - Dransfield, Mark T.

AU - Han, Mei Lan K.

AU - Martinez, Fernando J.

N1 - Funding Information: Conflict of interest: J.K. Krishnan reports receiving grants from the NHLBI/NIH during the conduct of the study. H. Voelker has nothing to disclose. J.E. Connett has nothing to disclose. D.E. Niewoehner reports receiving grants from the NIH during the conduct of the study, and personal fees from Boehringer Ingelheim, AstraZeneca and GlaxoSmithKline, outside the submitted work. R.K. Albert has nothing to disclose. P.D. Scanlon reports receiving grants from NHLBI during the conduct of the study; and clinical research grants from AstraZeneca, Boehringer Ingelheim, Forest Pharmaceuticals, GlaxoSmithKline, Novartis and Pearl Therapeutics, and consultancy fees paid to his institution by Boehringer Ingelheim and GlaxoSmithKline, outside the submitted work. G.J. Criner reports receiving grants from Boehringer Ingelheim, Novartis, AstraZeneca, Respironics, MedImmune, Actelion, Forest, Pearl, Ikaria, Aeris, PneumRx and Pulmonx, an equity interest in HGE Health Care Solutions, Inc., and consultancy for Amirall, Boehringer Ingelheim and Holaira, outside the submitted work. M.T. Dransfield reports receiving grants from the NHLBI during the conduct of the study; and grants from the Dept of Defense, fees for consulting and contracted clinical trials from Boehringer Ingeheim, GlaxoSmithKline, AstraZeneca and Boston Scientific, support for contracted clinical trials from Novartis, Yungjin, PneumRx/BTG and Pulmonx, and consulting fees from Genentech, outside the submitted work. M.K. Han reports receiving personal fees from Boehringer Ingelheim, GlaxoSmithKline and AstraZeneca, and nonfinancial support from Novartis and Sunovion, outside the submitted work. F.J. Martinez reports receiving nonfinancial support from GlaxoSmithKline for the NHLBI-supported parent study; and personal fees for a chronic cough CME programme from Continuing Education, personal fees for service on a COPD steering committee from Forest Laboratories, service on a COPD advisory board for Janssen, personal fees for service on a COPD steering committee, COPD advisory boards, a COPD Food and Drug Administration mock presentation and service on a COPD study data and safety monitoring board from GlaxoSmithKline, personal fees for service on a COPD study steering committee, COPD advisory boards and a CME presentation from Nycomed/Takeda, personal fees for service on COPD advisory boards and a steering committee, an ACO steering committee and COPD presentations from AstraZeneca, personal fees for service on COPD advisory boards, a COPD steering committee and COPD CME presentations from Boehringer Ingelheim, personal fees for service on COPD and IPF advisory boards from Bellerophon (formerly Ikaria) and Genentech, personal fees for service on COPD advisory boards and CME presentations from Novartis, personal fees for service on COPD advisory boards and COPD study steering committees from Pearl, personal fees for service on COPD advisory board from Roche, Sunovion, Theravance and ConCert Pharmaceuticals, personal fees for COPD CME programmes from CME Incite, the Annenberg Center for Health Sciences at Eisenhower, Integritas, Paradigm Medical Communications, LLC, and PeerVoice, Haymarket Communications, the Western Society of Allergy and Immunology, Prime Healthcare Ltd, WebMD and the PeerView Network, personal fees for a COPD/ACO teleconference from InThought, personal fees for COPD and IPF CME programmes from the National Association for Continuing Education, personal fees for COPD CME materials from UpToDate, personal fees for COPD telephone consultations from Proterixbio (formerly Bioscale) and Unity Biotechnology, personal fees for an ACO syndrome teleconference from Lucid, personal fees for COPD CME grand rounds from Methodist Hospital and Columbia University, personal fees for an ACO CME programme from the California Society of Allergy and Immunology, and personal fees for COPD CME presentations from Chiesi and the Puerto Rico Thoracic Society, outside the submitted work.

PY - 2019/3/1

Y1 - 2019/3/1

UR - http://www.scopus.com/inward/record.url?scp=85063259365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063259365&partnerID=8YFLogxK

U2 - 10.1183/13993003.01377-2018

DO - 10.1183/13993003.01377-2018

M3 - Letter

C2 - 30819817

AN - SCOPUS:85063259365

VL - 53

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 3

M1 - 1801377

ER -